MacroGenics

MacroGenics, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MacroGenics reports revenue growth and promising clinical updates in Q4

MacroGenics delivered strong financial performance with revenue growth and cost reductions in 2022.
The company faces challenges in study modifications, dose optimization, and patient evaluation for its key products.
Opportunities lie in expanding product studies, strategic partnerships, and optimizing treatment efficacy.
Overall, MacroGenics shows promise in financial stability, product development, and market positioning.

MacroGenics reports Q1 revenue growth amidst net loss challenges

MacroGenics showed mixed financial performance in Q1 2023 with revenue growth but a significant net loss.
The company's strengths lie in its anticipated cash runway, FDA approvals, and expected milestone payments.
Challenges include managing expenses, improving financial performance, and addressing analyst inquiries.
Opportunities exist in revenue growth, clinical programs, FDA approvals, and strategic partnerships.

MacroGenics reports Q2 results, projects strong pipeline growth ahead

MacroGenics' Q2 2023 performance reflects mixed financial results but strong progress in pipeline development and strategic partnerships.
The company's financial stability, ongoing innovation, and revenue potential position it well for future growth and value creation.
Challenges in data disclosure, enrollment criteria, and dose optimization require careful navigation, but present opportunities for market expansion and program enhancement.

MacroGenics reports improved Q3 earnings, eyes strategic partnerships for growth

MacroGenics demonstrated improved financial performance in Q3 2023, with a focus on cost management and strategic pipeline advancements.
The company's efforts to secure non-dilutive capital, explore partnerships, and drive innovation in ADC development position it for future growth.
Challenges lie in revenue generation, market differentiation, and resource allocation, but opportunities exist in collaborations, tumor type expansion, and technological advancements.

MacroGenics reports revenue decline but advances in clinical programs

MacroGenics faced a decline in revenue but made progress in its clinical programs and pipeline advancements.
Challenges include data transparency, patient enrollment, and managing treatment side effects.
Opportunities lie in potential Phase III trials, revenue growth prospects, and advancements in patient treatment.

MacroGenics reports strong Q1 results, eyes expansion and combination therapies

MacroGenics' Q1 2024 performance showed promising results with strong revenue and ongoing research advancements.
The company's focus on expanding studies, improving tolerability, and exploring combination therapies presents growth opportunities.
Challenges include ongoing investigations into safety protocols and evaluation of patient outcomes.
Overall, MacroGenics' strategic plans and positive efficacy outcomes position them well for future growth and development.

MacroGenics reports stellar Q3 earnings, CEO transition announced

MacroGenics delivered impressive financial results in Q3 2024, marked by substantial revenue growth, increased net income, and a solid cash balance supported by strategic initiatives.
While facing challenges in managing rising expenses and navigating a CEO transition, the company's diverse clinical pipeline and strong financial position present opportunities for future growth and innovation.
Investors should monitor how MacroGenics addresses cost management, sustains operational momentum during leadership changes, and capitalizes on its strengths to drive continued success in the biopharmaceutical sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Macrogenics, Inc. (NASDAQ: MGNX) on behalf of long-term stockholders following a class action complaint that was filed against MGNX on July 26, 2024 with a Class Period from March 7, 2024 to May 9, 2024. Our investigation concerns whether the board of directors of MGNX have breached their fiduciary duties to the company.

MGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month:

MacroGenics to Participate in Upcoming Investor Conference

ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month:

MacroGenics to Participate in Upcoming Investor Conferences

The headline numbers for MacroGenics (MGNX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About MacroGenics (MGNX) Q3 Earnings

MacroGenics (MGNX) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to loss of $0.52 per share a year ago.

MacroGenics (MGNX) Beats Q3 Earnings and Revenue Estimates

MacroGenics, Inc. (NASDAQ:MGNX ) Q2 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants James Karrels - Senior Vice President, Chief Financial Officer and Secretary Scott Koenig - President and Chief Executive Officer Conference Call Participants Nicholas Lorusso - TD Cowen Jonathan Chang - Leerink Partners Reena Patel - Citi Etzer Darout - BMO Capital Markets Jonathan Miller - Evercore ISI Silvan Tuerkcan - Citizens JMP Securities Mayank Mamtani - B. Riley Securities Peter Lawson - Barclays Stephen Willey - Stifel Operator Good afternoon.

MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Transcript

ROCKVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2024.

MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results

ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company's Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the transition process.

MacroGenics Announces Leadership Transition

ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2024 after the market closes on Tuesday, November 5, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, November 5, 2024, at 4:30 pm ET.

MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call

WILMINGTON, DE / ACCESSWIRE / October 25, 2024 / Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ GS:MGNX) on behalf of stockholders.

Rigrodsky Law, P.A. Is Investigating MacroGenics, Inc. On Behalf of Shareholders

ROCKVILLE, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)--MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, and TerSera Therapeutics LLC, a privately-held biopharmaceutical company with a focus in oncology and non-opioid pain management, announced today that they have entered into an agreement in which TerSera will acquire global rights to MARGENZA® (mar.

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®

NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX).

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNX

NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104928&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – MGNX

NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104874&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 - MGNX

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX).

Shareholders of MacroGenics, Inc. Should Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNX

NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104834&wire=1 or contact Joseph E. Levi, Esq.

Contact Levi & Korsinsky by September 24, 2024 Deadline to Join Class Action Against MacroGenics, Inc.(MGNX)

LOS ANGELES, CA / ACCESSWIRE / September 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 7, 2024 and May 9, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 24, 2024.

The Schall Law Firm Invites Investor Participation In A Securities Fraud Case Against MacroGenics, Inc.

LOS ANGELES--(BUSINESS WIRE)--MGNX Investors Have Opportunity to Join MacroGenics, Inc. Fraud Investigation with the Schall Law Firm.

MGNX Investors Have Opportunity to Join MacroGenics, Inc. Fraud Investigation with the Schall Law Firm

NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104815&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for Investors - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / September 24, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired MacroGenics securities between March 7, 2024, and May 9, 2024, inclusive (the "Class Period").

FINAL REMINDER MGNX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts MacroGenics, Inc. Investors to Participate in the Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104807&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MGNX

RADNOR, PA / ACCESSWIRE / September 24, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. ("MacroGenics") (NASDAQ:MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period" The lead plaintiff deadline is September 24, 2024. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered MacroGenics losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/macrogenics-inc?utm_source=PR&utm_medium=link&utm_campaign=mgnx&mktm=r You can also contact attorney Jonathan Naji, Esq.

Final MGNX Deadline Reminder: September 24, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

SAN FRANCISCO, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now.

Hagens Berman Alerts MacroGenics (MGNX) Investors to Today's Lead Plaintiff Deadline in Securities Class Action

NEW YORK , Sept. 24, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) of a class action securities lawsuit.

MacroGenics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGNX

NEW YORK, NY / ACCESSWIRE / September 23, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104700&wire=1 or contact Joseph E. Levi, Esq.

News for MacroGenics Stock (MGNX)